Form D · Biotechnology

SYNERGY PHARMACEUTICALS, INC.

New York, NY · CIK 0001347613

Offering snapshot reported Jun 20, 2011 · SEC filing

Reported sold
$1.16M
Offering amount: $2.16M
Investors reported
9
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jun 3, 2011
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jun 20, 2011Initial$1,161,243No comparison9SEC filing
Aug 20, 2010Initial$400,000No comparison1SEC filing
Dec 15, 2005PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Equity, Option to acquire
Exemptions
06
Duration over one year
No
Business combination
No
Sales commissions
$137K
Finders' fees
$0
Form D file number
021-161496

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Enclave Capital22732

Source: Form D, filed Jun 20, 2011. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Thomas Adams Director
John Brancaccio Director
Gabriele Cerrone Director
Gabriel M Cerrone Director
Bernard Denoyer Executive
Gary Jacob Director, Executive
Alan Joslyn Director
Christopher Mc Guigan Director
Chris Mc Guigan Director
Kunwar Shailubhai Executive
Melvin Spigelman Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
420 Lexington Avenue Suite 1609
New York, NY, 10170